Why the study?
Does diflunisal affect platelet aggregation and clinical bleeding in patients with pain and normal subjects?
Does diflunisal affect platelet aggregation and clinical bleeding in patients with pain and normal subjects?
Diflunisal at 250 mg twice or three times daily does not significantly impair platelet function or cause clinical bleeding.
Answers are grounded in this paper and cite their sources.
Diflunisal may be platelet-sparing in this cohort; should not yet change practice and leaves open need for RCTs.
The effect of the non-steroidal analgesic diflunisal on platelet aggregation and clinical haemorrhage at a dosage 250 mg twice or 3-times daily, sufficient to relieve musculo-skeletal pain and other painful conditions, was studied in 15 patients and 5 normal subjects. Platelet aggregation was carried out with ADP and collagen before and during treatment with diflunisal. The results indicated that diflunisal is an effective analgesic with no significant adverse effect on platelet function or clinical bleeding.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: